Michael W. Scherz

1.6k total citations
25 papers, 1.1k citations indexed

About

Michael W. Scherz is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Michael W. Scherz has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 6 papers in Organic Chemistry and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Michael W. Scherz's work include Pharmacological Receptor Mechanisms and Effects (6 papers), Receptor Mechanisms and Signaling (6 papers) and Sphingolipid Metabolism and Signaling (5 papers). Michael W. Scherz is often cited by papers focused on Pharmacological Receptor Mechanisms and Effects (6 papers), Receptor Mechanisms and Signaling (6 papers) and Sphingolipid Metabolism and Signaling (5 papers). Michael W. Scherz collaborates with scholars based in United States, Switzerland and Italy. Michael W. Scherz's co-authors include Oliver Nayler, Jasper Dingemanse, Patrick Hess, Thomas Weller, Martine Clozel, Walter Fischli, Changbin Qiu, Ralf Koberstein, Catherine Brisbare‐Roch and François Jenck and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Michael W. Scherz

25 papers receiving 1.1k citations

Peers

Countries citing papers authored by Michael W. Scherz

Since Specialization

Citations

This map shows the geographic impact of Michael W. Scherz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Scherz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Scherz more than expected).

Fields of papers citing papers by Michael W. Scherz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Scherz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Scherz. The network helps show where Michael W. Scherz may publish in the future.

Co-authorship network of co-authors of Michael W. Scherz

This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Scherz. A scholar is included among the top collaborators of Michael W. Scherz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Scherz. Michael W. Scherz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacological Profile of MP-101, a Novel Non-racemic Mixture of R- and S-dimiracetam with Increased Potency in Rat Models of Cognition, Depression and Neuropathic Pain 2022 ·Cells ·Tiziana Bonifacino, Laura Micheli, Carola Torazza, Carla Ghelardini, Carlo Farina, Giambattista Bonanno, Marco Milanese, Lorenzo Di Cesare Mannelli, Michael W. Scherz	2
2	A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin 2017 ·Cancer Chemotherapy and Pharmacology ·Lorenzo Di Cesare Mannelli, Mario Maresca, Laura Micheli, Carlo Farina, Michael W. Scherz, Carla Ghelardini	23
3	A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam 2015 ·NeuroToxicology ·Lorenzo Di Cesare Mannelli, Mario Maresca, Carlo Farina, Michael W. Scherz, Carla Ghelardini	11
4	Effects of Dimiracetam on oxaliplatin-induced hyperalgesia and allodynia in the rat. 2015 ·Journal of Clinical Oncology ·Lorenzo Di Cesare Mannelli, Laura Micheli, Carlo Farina, Michael W. Scherz, Carla Ghelardini	1
5	Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P₁receptor modulator: Favorable impact of dose up-titration 2014 ·The Journal of Clinical Pharmacology ·Patrick Brossard, Michael W. Scherz, Atef Halabi, Haidar Maatouk, Andreas Krause, Jasper Dingemanse	58
6	Novel S1P₁ Receptor Agonists – Part 1: From Pyrazoles to Thiophenes 2013 ·Journal of Medicinal Chemistry ·Martin H. Bolli, (unknown), (unknown), Stefan Abele, Magdalena Birker, Roberto Bravo, Daniel Bur, Patrick Hess, Christopher Kohl, David F. Lehmann, Oliver Nayler, Markus Rey, Solange Meyer, Michael W. Scherz, G. Schmidt, Beat Steiner, Alexander Treiber, (unknown), Thomas Weller	18
7	Novel S1P₁ Receptor Agonists − Part 3: From Thiophenes to Pyridines 2013 ·Journal of Medicinal Chemistry ·Martin H. Bolli, Stefan Abele, Magdalena Birker, Roberto Bravo, Daniel Bur, Ruben de Kanter, Christopher Kohl, (unknown), Patrick Hess, Cyrille Lescop, (unknown), (unknown), Oliver Nayler, Markus Rey, Michael W. Scherz, G. Schmidt, Jürgen Seifert, Beat Steiner, (unknown), Thomas Weller	15
8	Promotion of sleep by targeting the orexin system in rats, dogs and humans 2007 ·Nature Medicine ·Catherine Brisbare‐Roch, Jasper Dingemanse, Ralf Koberstein, Petra Hoever, Hamed Aissaoui, (unknown), (unknown), Oliver Nayler, Joop van Gerven, Sanne Lysbet de Haas, Patrick Hess, Changbin Qiu, Stephan Buchmann, Michael W. Scherz, Thomas Weller, Walter Fischli, Martine Clozel, François Jenck	452
9	Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Martine Clozel, Christoph A. Binkert, Magdalena Birker, (unknown), Shuangshuang Ding, Walter Fischli, Patrick Hess, (unknown), Keith Morrison, (unknown), (unknown), Oliver Nayler, Changbin Qiu, Markus Rey, Michael W. Scherz, (unknown), Thomas Weller, (unknown), (unknown)	108
10	UROTENSIN II MEDIATES ERK1/2 PHOSPHORYLATION AND PROLIFERATION IN GPR14-TRANSFECTED CELL LINES 2002 ·Journal of Receptors and Signal Transduction ·(unknown), (unknown), Bénédicte Haenig, Michael W. Scherz, Oliver Nayler	47
11	Stereoselective Interactions of the Enantiomers of Chromanol 293B with Human Voltage-Gated Potassium Channels 2000 ·Journal of Pharmacology and Experimental Therapeutics ·Iris Chun-Hui Yang, Michael W. Scherz, Anthony Bahinski, Paul B. Bennett, Katherine T. Murray	38
12	New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 2. 7-tert-Butyl-2,3-dihydro-3,3-dimethylbenzofuran Derivatives as Gastrointestinal Safe Antiinflammatory and Analgesic Agents: Variations of the Dihydrobenzofuran Ring 1998 ·Journal of Medicinal Chemistry ·John M. Janusz, Patricia A. Young, Michael W. Scherz, (unknown), (unknown), (unknown), Stanisław Pikul, (unknown), Carl R. Johnson, C. B. W. Senanayake, David E. Kellstein, (unknown), (unknown), Theresa Rosario-Jansen, I. Jack Magrisso, Kenneth R. Wehmeyer, (unknown), Thomas H. Eichhold, Roy L. M. Dobson	30
13	New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 2. 7-tert-Butyl-2,3-dihydro-3,3-dimethylbenzofuran Derivatives as Gastrointestinal Safe Antiinflammatory and Analgesic Agents: Variations of the Dihydrobenzofuran Ring 1998 ·Journal of Medicinal Chemistry ·John M. Janusz, Patricia A. Young, Michael W. Scherz, (unknown), (unknown), (unknown), Stanisław Pikul, (unknown), Carl R. Johnson, C. B. W. Senanayake, David E. Kellstein, (unknown), (unknown), Theresa Rosario-Jansen, I. Jack Magrisso, Kenneth R. Wehmeyer, (unknown), Thomas H. Eichhold, Roy L. M. Dobson	3
14	Analysis of a novel antiinflammatory agent, 1-(7-tert.-butyl-2,3-dihydro-3,3-dimethylbenzo[b]furan-5-yl)-4-cyclopropylbutan-1-one (PGV-20229), in plasma matrices by stable-isotope-dilution gas chromatography-mass spectrometry 1997 ·Journal of Chromatography B Biomedical Sciences and Applications ·(unknown), Michael W. Scherz, (unknown), Kenneth R. Wehmeyer	2
15	Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogs, high-affinity ligands for the haloperidol-sensitive .sigma. receptor 1990 ·Journal of Medicinal Chemistry ·Michael W. Scherz, (unknown), James B. Fischer, N. Laxma Reddy, Alfred C. Server, Mark S. Sonders, (unknown), Eckard Weber, Scott T. Wong, John F. W. Keana	36
16	Synthesis and characterization of a series of diarylguanidines that are noncompetitive N-methyl-D-aspartate receptor antagonists with neuroprotective properties. 1989 ·Proceedings of the National Academy of Sciences ·John F. W. Keana, Robert McBurney, Michael W. Scherz, James B. Fischer, (unknown), Stephen M. Smith, Alfred C. Server, Steven Finkbeiner, Charles F. Stevens, Craig E. Jahr	39
17	Sigma receptors regulate contractions of the guinea pig ileum longitudinal muscle/myenteric plexus preparation elicited by both electrical stimulation and exogenous serotonin 1989 ·Journal of Neuroscience ·(unknown), Michael W. Scherz, (unknown), E Weber	65
18	Synthesis and characterization of a radiolabelled derivative of the phencyclidine/N-methyl-D-aspartate receptor ligand (+)MK-801 with high specific radioactivity 1988 ·Life Sciences ·John F. W. Keana, Michael W. Scherz, M Quarum, Mark S. Sonders, Eckard Weber	11
19	Synthesis and characterization of an affinity label for brain receptors to psychotomimetic benzomorphans: differentiation of σ-type and phencyclidine receptors 1987 ·European Journal of Pharmacology ·(unknown), (unknown), Mark S. Sonders, (unknown), (unknown), Michael W. Scherz, John F. W. Keana, Eckard Weber	11
20	Kristall- und Molekülstruktur von 5.10-Dihydro-5.10-diniethylphenaziniiimtniodid und 5.10-Dihydro-5.10-diethylphenaziniumtriiodid / Molecular and Crystal Structure of 5,10-Dihydro-5.10-dimethylphenaziniumtriiodide and 5.10-Dihydro-5.10-diethylphenazinium triiodide 1978 ·Zeitschrift für Naturforschung B ·H. J. Keller, (unknown), D. Nöthe, Michael W. Scherz, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact